ClinicalTrials.gg
RecruitingNCT07483502Updated Jun 23, 2026

The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.

An interventional study of 5g of prebiotic fibre and 300mg of magnesium (WellBiome) and 5g of maltodextrin in Cardiovascular Diseases (CVD) and Cardiovascular Surgery, sponsored by Hull University Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Hull University Teaching Hospitals NHS Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

More than 7.4 million people in the UK are currently waiting for surgery. Behind that number are real people-patients preparing mentally and physically for procedures ranging from joint replacements to major heart and abdominal operations.

This research forms part of a broader strategy known as prehabilitation - preparing the body before surgery to improve outcomes afterward. For patients waiting for surgery, it represents a shift from passive waiting to active preparation.

Heart surgery for bypass or valve replacements results in inevitable yet controlled trauma. It increases inflammation, stress hormones and immune system demand. The body then has to repair itself - quickly and efficiently. And here's the surprising part. Inside your gut live trillions of bacteria - called your gut microbiome. These bacteria help regulate inflammation, strengthen your immune system and protect against infection.

This randomised clinical trial is investigating a fascinating question:

Can improving your gut microbiome through consumption of fibre before surgery help you recover faster, reduce time in ICU, shorten hospital stays, and lower complication rates? The placebo controlled trial will randomise 80 patients following eligibiilty checks to either 5g of prebiotic fibre/300mg of magnesium (WellBiome) OR 5g of maltodextrin for a period of 6-8 weeks prior to surgery. Patient will provide blood, urine and faecal samples at baseline and upon admission for surgery, and two further blood samples at day 3 and 6 post operatively.

Following surgery, patient outcomes will be assessed and compared between the experimental group (prebiotic fibre/magnesium) and placebo group (maltodextrin). The investigators are focussing on the time spent in the intensive care unit, complications and overall hospital stay. By documenting and quantifying these the investigators can calculate the costs and any savings between the groups.

02

Conditions studied

  • Cardiovascular Diseases (CVD)
  • Cardiovascular Surgery

Keywords

  • Cardiac surgery
  • Surgical outcomes
  • Nutritional prehabilitation
  • Microbiome
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Hull University Teaching Hospitals NHS Trust is the lead sponsor of 95 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50-80
  • ≥ 25-40kg/m²
  • Waist circumference >94cm (men) and 88cm (women)
  • 42-58 mmol/mol (6.0-7.5 old HbA1c units)
  • No known intolerances to oligosaccharides and xylooligosaccharides
  • Be stable dose of cholesterol and blood pressure medication for 3 months
  • Be willing to participate and sign to that effect.

Exclusion criteria

EXCLUSION CRITERIA

  • Active cancer
  • Any gastro-intestinal surgery or currently under the care of the GI clinical team for any digestive issue (Crohn's, IBS, ulcerative colitis).
  • On or had antibiotic treatment in the last 3 months.
  • Patients who have taken ibuprofen in the last week or any condition that increases the likelihood of regular or sustained use during the intervention.
  • On proton pump inhibitors (Omeprazole, Esomeprazole, Lansoprazole, Rabeprazole, Pantoprazole) within the last one month on long acting non-steroidal anti-inflammatory drugs in the last month or any condition that increases the likelihood of regular use during the intervention.
  • Taking any prebiotic or probiotic supplementation within the last three months
  • Patients who are vegetarians or vegans
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    A matching placebo containing 5g of maltodextrin

    Dietary Supplement: 5g of maltodextrin

  • Experimental
    Experimental

    A microbiome modulator containing 5g of prebiotic fibres and 300mg of magnesium (WELLBIOME)

    Dietary Supplement: 5g of prebiotic fibre and 300mg of magnesium (WellBiome)

Interventions

  • Dietary supplement5g of prebiotic fibre and 300mg of magnesium (WellBiome)

    5g of prebiotic fibre and 300mg of magnesium (WellBiome)

  • Dietary supplement5g of maltodextrin

    A matched placebo of 5g maltodextrin

06

What researchers measure

Primary outcomes

  1. ICU time (hours)

    1\. Time in ICU (hours) The total time in hours spent in the ICU, calculated from ICU admission following cardiac surgery to ICU discharge to the general cardiology ward

    Time frame: From ICU admission until ICU discharge, up to 30 days

  2. Complications post cardiac surgery

    The number of Society of Cardio-thoracic Surgery register of complications

    Time frame: Number of complications following cardiac surgery, up to 30 days.

  3. Length of hospital stay (days)

    Length of hospital stay from admission to medical discharge

    Time frame: From hospital admission until hospital discharge, up to 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We will share the clinical study report and derived data with researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the study steering committee.

Supporting information: Clinical study report

Time frame: Starting 6 months following publication and ending 5 years after publication.

Access criteria: Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the study steering committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 6 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Oct 28, 2026
CompletionEst.
Dec 18, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483502
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 9, 2026
Primary completion
Oct 28, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Jun 23, 2026

Study contacts

James Philip Hobkirk, PhD
Contact
james.hobkirk3@nhs.net
+44 (0) 7894 264660

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion